{"DataElement":{"publicId":"5206892","version":"1","preferredName":"Hormone Replacement Therapy Pharmaceutical Formulation Other Specify","preferredDefinition":"The form of hormone replacement therapy the participant has used that has not been previously listed.","longName":"HRMN_REP_FORM_SPEC","context":"BBRB","contextVersion":"1","DataElementConcept":{"publicId":"5205056","version":"1","preferredName":"Hormone Replacement Therapy Pharmaceutical Formulation","preferredDefinition":"Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production._The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","longName":"2436239v1.0:5205054v1.0","context":"BBRB","contextVersion":"1","ObjectClass":{"publicId":"2436239","version":"1","preferredName":"Hormone Replacement Therapy","preferredDefinition":"RAEB: Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.","longName":"C15599","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Replacement Therapy","conceptCode":"C15599","definition":"Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06F397CB-46AF-08F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-12-12","modifiedBy":"ONEDATA","dateModified":"2005-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5205054","version":"1","preferredName":"Pharmaceutical Formulation","preferredDefinition":"The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","longName":"C42638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmaceutical Formulation","conceptCode":"C42638","definition":"The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EFD7A53-7676-169F-E050-BB89AD432600","latestVersionIndicator":"Yes","beginDate":"2016-03-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-03-26","modifiedBy":"ONEDATA","dateModified":"2016-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"BPV: Biospecimen Pre-analytical Variables (BPV) Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EFD7A53-7687-169F-E050-BB89AD432600","latestVersionIndicator":"Yes","beginDate":"2016-03-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-03-26","modifiedBy":"HARTLEYG","dateModified":"2016-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5188870","version":"1","longName":"BPV - Tumor Biospecimen Acquisition","context":"BBRB","ClassificationSchemeItems":[{"publicId":"5405791","version":"1","longName":"BPV - Tumor Biospecimen Acquisition","context":"BBRB"},{"publicId":"6736428","version":"1","longName":"Ovary Clinical Data Entry","context":"BBRB"}]}],"AlternateNames":[{"name":"BBRB","type":"USED_BY","context":"BBRB"}],"ReferenceDocuments":[{"name":"Form of hormone replacement t","type":"Preferred Question Text","description":"Form of hormone replacement therapy - other","url":null,"context":"BBRB"}],"origin":"BPV: Biospecimen Pre-analytical Variables (BPV) Program","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2F36E331-B9ED-DEFD-E050-BB89AD43555B","latestVersionIndicator":"Yes","beginDate":"2016-03-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-03-29","modifiedBy":"HARTLEYG","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}